Peptide Receptor Radionuclide Therapy (PRRT)

Peptide Receptor Radionuclide Therapy (PRRT) is a treatment for neuroendocrine cancer. It involves four cycles spaced around eight weeks apart. You'll stay overnight in the hospital for each session. Between cycles, regular tests will be done to make sure it's safe for you to move on to the next one. Since this treatment involves radioactivity, there are some simple precautions to follow after each cycle, and these will be explained to you.

 

How does it work?

PRRT delivers radiation therapy to any tumours in your body. It uses a radioactive substance that targets receptors called “somatostatin”, which is mainly found in neuroendocrine tumours. The recommended PRRT for you is called Lutathera®, which contains the radioactive element Lutetium-177 (Lu-177). This element releases radiation over a short distance in your body, targeting tumour cells while sparing nearby healthy tissue.